↓ Skip to main content

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, January 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
5 news outlets
twitter
7 X users
patent
1 patent
wikipedia
1 Wikipedia page

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
29 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
Published in
Journal for Immunotherapy of Cancer, January 2019
DOI 10.1186/s40425-018-0470-3
Pubmed ID
Authors

Kerstin Kapp, Barbara Volz, Michael A. Curran, Detlef Oswald, Burghardt Wittig, Manuel Schmidt

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 29 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 17%
Student > Ph. D. Student 4 14%
Student > Bachelor 3 10%
Student > Doctoral Student 2 7%
Student > Master 2 7%
Other 3 10%
Unknown 10 34%
Readers by discipline Count As %
Agricultural and Biological Sciences 4 14%
Medicine and Dentistry 4 14%
Immunology and Microbiology 3 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Biochemistry, Genetics and Molecular Biology 2 7%
Other 4 14%
Unknown 10 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 49. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 August 2021.
All research outputs
#851,921
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#202
of 3,424 outputs
Outputs of similar age
#19,816
of 446,389 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#6
of 81 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,424 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,389 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 81 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.